Form 4: AngioDynamics CEO James Clemmer Reports Acquisition of Restricted Stock Units and Performance Rights

James Clemmer, President and CEO of AngioDynamics, reports the acquisition of restricted stock units and performance rights, along with stock options.

Summary

• James C. Clemmer, the President and CEO of AngioDynamics Inc., filed a Form 4 detailing changes in beneficial ownership.
• On July 17, 2024, Clemmer acquired 105,811 shares of common stock in the form of restricted stock units, vesting in equal annual installments starting July 17, 2025.
• Clemmer also acquired 211,622 performance rights, each representing a contingent right to receive one share of common stock, with the number of shares earned based on total shareholder return relative to a peer group over a three-year period.
• Additionally, Clemmer already held 207,693 non-qualified stock options with an exercise price of $7.4, vesting in equal annual installments starting July 17, 2025.
• Following these transactions, Clemmer directly owns 644,877 shares of AngioDynamics common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of equity-based compensation is a standard practice and aligns management's interests with shareholders. The vesting schedule encourages long-term commitment.

Positives

• The acquisition of restricted stock units and performance rights aligns the CEO's interests with those of the shareholders, incentivizing performance and long-term value creation.
• The vesting schedules for the restricted stock units and stock options encourage continued service and commitment from the CEO.

Risks

• The value of the performance rights is contingent on AngioDynamics' total shareholder return relative to its peer group, which may be subject to market volatility and industry-specific challenges.
• If performance targets are not met, a portion or all of the performance rights may be forfeited.

Future Outlook

The vesting of restricted stock units and stock options over the next four years suggests an expectation of continued growth and value creation at AngioDynamics.

Industry Context

The granting of stock-based compensation is a common practice in the medical device industry to attract and retain top talent and align their interests with those of shareholders. Performance-based equity awards are increasingly used to incentivize specific strategic goals.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the medical device industry, with vesting schedules typically ranging from three to five years.
• Performance-based equity awards, such as the performance rights granted to Clemmer, are often tied to metrics like revenue growth, profitability, or total shareholder return, aligning executive compensation with company performance.
• Comparable companies like Boston Scientific, Medtronic, and Stryker also utilize a mix of stock options, restricted stock units, and performance-based equity awards in their executive compensation packages.

Stakeholder Impact

• Shareholders may view the equity-based compensation favorably as it aligns management's interests with long-term value creation.
• Employees may be motivated by the potential for future equity grants and the company's focus on performance-based compensation.

Key Dates